|
1
|
Siegel RL, Miller KD and Jamal A: Cancer
statistics 2018. CA Cancer J Clin. 68:7–30. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Manfredi S, Lepage C, Hatem C, Coatmeur O,
Faivre J and Bouvier AM: Epidemiology and management of liver
metastases from colorectal cancer. Ann Surg. 244:254–259.
2006.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kopetz S, Chang GJ, Overman MJ, Eng C,
Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM and
McWilliams RR: Improved survival in metastatic colorectal cancer is
associated with adoption of hepatic resection and improved
chemotherapy. J Clin Oncol. 27:3677–3683. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Fong Y, Fortner J, Sun RL, Brennan MF and
Blumgart LH: Clinical score for predicting recurrence after hepatic
resection for metastatic colorectal cancer: Analysis of 1001
consecutive cases. Ann Surg. 230:309–321. 1999.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Boysen AK, Spindler KL, Høyer M, Mortensen
FV, Christensen TD, Farkas DK and Ording AG: Metastasis directed
therapy for liver and lung metastases from colorectal cancer-a
population based study. Int J Cancer. 143:3218–3226.
2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Ramming KP, Sparks FC, Eilber FR, Holmes
EC and Morton DL: Hepatic artery ligation and 5-fluorouracil
infusion for metastatic colon carcinoma and primary hepatoma. Am J
Surg. 132:236–242. 1976.PubMed/NCBI View Article : Google Scholar
|
|
7
|
van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dzodic R, Gomez-Abuin G, Rougier P, Bonnay
M, Ardouin P, Gouyette A, Rixe O, Ducreux M and Munck JN:
Pharmacokinetic advantage of intra-arterial hepatic oxaliplatin
administration: Comparative results with cisplatin using a rabbit
VX2 tumor model. Anticancer Drugs. 15:647–650. 2004.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6(224ra24)2014.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Leon SA, Shapiro B, Sklaroff DM and Yaros
MJ: Free DNA in the serum of patients and the effect of therapy.
Cancer Res. 37:646–650. 1977.PubMed/NCBI
|
|
11
|
Spindler KG, Boysen AK, Pallisgaard N,
Johansen JS, Tabernero J, Sørensen MM, Jensen BV, Hansen TF,
Sefrioui D, Andersen RF, et al: Cell free DNA in metastatic
colorectal cancer: A systematic review and meta analysis.
Oncologist. 22:1049–1055. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zarkavelis G, Boussios S, Papadaki A,
Katsanos KH, Christodoulou DK and Pentheroudakis G: Current and
future biomarkers in colorectal cancer. Ann Gastroenterol.
30:613–621. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Vittrup BV, Nørgaard H, Bergenfeldt M,
Larsen FO, Høgdall E, Johansen JS, Sidenius Johansen JS, Hermann HK
and Nielsen DL: Hepatic arterial infusion (HAI) of oxaliplatin with
capecitabine in first line treatment of patients (pts) with liver
limited metastases from colorectal cancer (LLmCRC). Abstracts
Gastrointestinal Tumours, Colorectal. 29: Suppl 8(viii173)2018.
|
|
14
|
Boysen AK, Sørensen BS, Lefevre AC,
Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D,
Taflin H, et al: Methodological development and biological
observations of cell free DNA with a simple direct fluorescent
assay in colorectal cancer. Clin Chim Acta. 487:107–111.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Goldshtein H, Hausmann MJ and Douvdevani
A: A rapid direct fluorescent assay for cell-free DNA
quantification in biological fluids. Ann ClinBiochem. 46:488–494.
2009.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Czeiger D, Shaked G, Sebbag G, Vakhrushev
A, Flomboym A, Lior Y, Belochitski O, Ariad S and Douvdevani A:
Elevated cell-free DNA measured by a simple assay is associated
with increased rate of colorectal cancer relapse. Am J Clin Pathol.
145:852–857. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Mocellin S, Pilati P, Lise M and Nitti D:
Meta-analysis of hepatic arterial infusion for unresectable liver
metastases from colorectal cancer: The end of an era? J Clin Oncol.
25:5649–5654. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xu J, Zhong Y, Weixin N, Xinyu Q, Yanhan
L, Li R, Jianhua W, Zhiping Y and Jiemin C: Preoperative hepatic
and regional arterial chemotherapy in the prevention of liver
metastasis after colorectal cancer surgery. Ann Surg. 245:583–590.
2007.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Kelly CM and Kemeny NE: Liver-directed
therapy in metastatic colorectal cancer. Expert Rev Anticancer
Ther. 17:745–758. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Spindler KL, Appelt AL, Pallisgaard N,
Andersen RF, Brandslund I and Jakobsen A: Cell-free DNA in healthy
individuals, noncancerous disease and strong prognostic value in
colorectal cancer. Int J Cancer. 135:2984–2991. 2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Boussios S, Ozturk MA, Moschetta M,
Karathanasi A, Zakynthinakis-Kyriakou N, Katsanos KH, Christodoulou
DK and Pavlidis N: The developing story of predictive biomarkers in
colorectal cancer. J Pers Med. 9(12)2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kim IH, Lee JE, Yang JH, Jeong JW, Ro S,
Oh ST, Kim JG, Choi MH and Lee MA: Clinical significance of
discordance between carcinoembryonic antigen levels and RECIST in
metastatic colorectal cancer. Cancer Res Treat. 50:283–292.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hermunen K, Lantto E, Poussa T, Haglund C
and Österlund P: Can carcinoembryonic antigen replace computed
tomography in response evaluation of metastatic colorectal cancer?
Acta Oncol. 57:750–758. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Berger AW, Schwerdel D, Welz H, Marienfeld
R, Schmidt SA, Kleger A, Ettrich TJ and Seufferlein T: Treatment
monitoring in metastatic colorectal cancer patients by
quantification and KRAS genotyping of circulating cell-free DNA.
PLoS One. 12(e0174308)2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Boysen AK, Wettergren Y, Sorensen BS,
Taflin H, Gustavson B and Spindler KG: Cell-free DNA levels and
correlation to stage and outcome following treatment of locally
advanced rectal cancer. Tumour Biol.
39(1010428317730976)2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Schou JV, Larsen FO, Sørensen BS, Abrantes
R, Boysen AK, Johansen JS, Jensen BV, Nielsen DL and Spindler KL:
Circulating cell-free DNA as predictor of treatment failure after
neoadjuvant chemo-radiotherapy before surgery in patients with
locally advanced rectal cancer. Ann Oncol. 29:610–615.
2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Boysen AK, Jensen M, Nielsen DT, Mortensen
FV, Sørensen BS, Jensen AR and Spindler KL: Cell-free DNA and
chemoembolization in patients with liver metastases from colorectal
cancer. Oncol Lett. 16:2654–2660. 2018.PubMed/NCBI View Article : Google Scholar
|
